Extracellular vesicles as advanced therapeutics for the resolution of organ fibrosis: Current progress and future...

Area of Science:

• Biomedical Science
• Regenerative Medicine
• Nanotechnology

Background:

• Organ fibrosis is a progressive condition affecting multiple organs, leading to dysfunction and failure.
• Current treatments are limited in their ability to halt or reverse fibrosis.
• There is a critical need for novel anti-fibrotic therapeutics.

Purpose of the Study:

• To review the potential of extracellular vesicles (EVs) as a therapeutic strategy for organ fibrosis.
• To discuss the mechanisms by which native and engineered EVs attenuate fibrosis.
• To explore the future development of EV-based nanotherapies for clinical application.

Main Methods:

• Review of preclinical studies on native and engineered EVs for organ fibrosis.
• Analysis of EV biology, production, and therapeutic mechanisms.
• Discussion of engineering strategies to enhance EV potency.

Main Results:

• Native EVs from various cell types demonstrate anti-fibrotic effects via anti-inflammation, pro-angiogenesis, myofibroblast inactivation, and ECM remodeling.
• Engineering strategies like genetic modification and reagent loading significantly boost EV therapeutic efficacy.
• EVs offer a versatile platform for developing advanced anti-fibrotic interventions.

Conclusions:

• Extracellular vesicles represent a promising cell-free therapeutic approach for organ fibrosis.
• EV-based nanotherapies hold potential for clinical translation in treating fibrotic diseases.
• Further research into EV engineering and delivery is crucial for optimizing anti-fibrotic treatments.